Grifols (GRFS) Cash & Equivalents (2010 - 2025)
Grifols (GRFS) reported Cash & Equivalents of $923.1 million for Q4 2025, down 11.85% on a YoY basis from $1.0 billion in Q4 2024, and down 11.85% quarter-over-quarter from $1.0 billion in Q4 2024.
Grifols (GRFS) Cash & Equivalents (2010 - 2025) Analysis & Trends
Grifols has reported Cash & Equivalents for 16 years, with the latest figure at $923.1 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents fell 11.85% year-over-year to $923.1 million; the trailing twelve-month figure through Dec 2025 stood at $923.1 million (down 11.85% YoY), and the FY2025 full-year result was $923.1 million, down 11.85% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $923.1 million, down from $1.0 billion in the prior quarter.
- The five-year high for Cash & Equivalents was $3.1 billion in Q4 2021, with the low at $560.1 million in Q4 2022.
- Historically, Cash & Equivalents has averaged $1.2 billion across 5 years, with a median of $923.1 million in 2025.
- Annual changes were most pronounced in 2021 — Cash & Equivalents soared 342.97% — and 2022, when it plunged 81.7%.
- Grifols' Cash & Equivalents stood at $3.1 billion in 2021, then sank by 81.7% to $560.1 million in 2022, then grew by 1.62% to $569.2 million in 2023, then soared by 83.99% to $1.0 billion in 2024, then retreated by 11.85% to $923.1 million in 2025.
- The last three Cash & Equivalents figures came in at $923.1 million (Q4 2025), $1.0 billion (Q4 2024), and $569.2 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.64 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 923.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 923.09 Mn |
| Dec 31, 2024 | 1.05 Bn |
| Dec 31, 2023 | 569.17 Mn |
| Dec 31, 2022 | 560.12 Mn |
| Dec 31, 2021 | 3.06 Bn |
| Dec 31, 2020 | 691.11 Mn |
| Sep 30, 2020 | 1.21 Bn |
| Mar 31, 2020 | -130.24 Mn |
| Dec 31, 2019 | 1.14 Bn |
| Sep 30, 2019 | 881.43 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Dec 31, 2018 | 1.18 Bn |
| Sep 30, 2018 | 676.95 Mn |
| Jun 30, 2018 | 797.82 Mn |
| Mar 31, 2018 | 21.42 Mn |
| Dec 31, 2017 | 1.04 Bn |
| Jun 30, 2017 | 824.90 Mn |
| Mar 31, 2017 | 156.72 Mn |
| Dec 31, 2016 | 966.36 Mn |
| Sep 30, 2016 | 1.01 Bn |